2026-04-17T10:44:46Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1803722025-11-20T15:04:03Zcom_2072_1057col_2072_478916col_2072_478917

urn:hdl:2445/180372 Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL) Genescà, Eulàlia Morgades, Mireia González Gil, Celia Fuster Tormo, Francisco Haferlach, Claudia Meggendorfer, Manja Montesinos, Pau Barba, Pere Gil, Cristina Coll, Rosa Moreno, María José Martínez Carballeira, Daniel García Cadenas, Irene Vives, Susana Ribera, Jordi González Campos, José Díaz Beyà, Marina Mercadal, Santiago Artola, María Teresa Cladera, Antonia Tormo, Mar Bermúdez, Arancha Vall Llovera, Ferran Martínez Sánchez, Pilar Amigo, María Luz Monsalvo, Silvia Novo, Andrés Cervera, Marta García Guiñon, Antonio Ciudad, Juana Cervera, José Hernández Rivas, Jesús María Granada, Isabel Haferlach, Torsten Orfao, Alberto Solé, Francesc Ribera, Josep Maria Citogenètica humana Leucèmia Pronòstic mèdic Human cytogenetics Leukemia Prognosis The potential prognostic value of conventional karyotyping in adult T-cell acute lymphoblastic leukemia (T-ALL) remains an open question. We hypothesized that a modified cytogenetic classification, based on the number and type of cytogenetic abnormalities, would allow the identification of high-risk adult T-ALL patients. Complex karyotype defined by the presence of ≥3 cytogenetic alterations identified T-ALL patients with poor prognosis in this study. Karyotypes with ≥3 abnormalities accounted for 16 % (22/139) of all evaluable karyotypes, corresponding to the largest poor prognosis cytogenetic subgroup of T-ALL identified so far. Patients carrying karyotypes with ≥3 cytogenetic alterations showed a significantly inferior response to therapy, and a poor outcome in terms of event-free survival (EFS), overall survival (OS) and cumulative incidence of relapse (CIR), independently of other baseline characteristics and the end-induction minimal residual disease (MRD) level. Additional molecular analyses of patients carrying ≥3 cytogenetic alterations showed a unique molecular profile that could contribute to understand the underlying molecular mechanisms of resistance and to evaluate novel targeted therapies (e.g. IL7R directed) with potential impact on outcome of adult T-ALL patients. 2021-10-04T07:32:18Z 2021-10-04T07:32:18Z 2021-10-01 2021-10-01T11:41:04Z info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Reproducció del document publicat a: https://doi.org/10.1016/j.leukres.2021.106612 Leukemia Research, 2021, vol. 109, p. 106612 https://doi.org/10.1016/j.leukres.2021.106612 cc by-nc-nd (c) Genescà, Eulàlia et al, 2021 http://creativecommons.org/licenses/by-nc-nd/3.0/es/ info:eu-repo/semantics/openAccess Elsevier BV Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))